RD3 loss dictates high-risk aggressive neuroblastoma and poor clinical outcomes
| Autor: | Faizan Haider Khan, Natarajan Aravindan, Vijayabaskar Pandian, Terence S. Herman, Mohan Natarajan, Sheeja Aravindan, Satish Kumar Ramraj, Seifollah Azadi |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Oncology
medicine.medical_specialty Pathology tumor suppressor Metastasis Neuroblastoma cell Mice neuroblastoma Cell Line Tumor Internal medicine Neuroblastoma medicine Animals Humans metastasis Metastasis suppressor Stage (cooking) Eye Proteins Survival analysis business.industry Cancer medicine.disease Survival Analysis 3. Good health Treatment Outcome high-risk aggressive neuroblastoma Tissue Array Analysis Disease Progression Heterografts RD3 business Research Paper Biomedical sciences |
| Zdroj: | Oncotarget |
| ISSN: | 1949-2553 |
| DOI: | 10.18632/oncotarget.5204 |
| Popis: | // Faizan H. Khan 1, * , Vijayabaskar Pandian 1, * , Satish Kumar Ramraj 1, * , Sheeja Aravindan 2 , Mohan Natarajan 3 , Seifollah Azadi 4 , Terence S. Herman 1, 2 , Natarajan Aravindan 1 1 Department of Radiation Oncology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA 2 Stephenson Cancer Center, Oklahoma City, OK, USA 3 Department of Pathology, University of Texas Health Sciences Center at San Antonio, San Antonio, TX, USA 4 Department of Cell Biology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA * These authors have contributed equally to this work Correspondence to: Natarajan Aravindan, e-mail: naravind@ouhsc.edu Keywords: RD3, neuroblastoma, tumor suppressor, high-risk aggressive neuroblastoma, metastasis Received: July 28, 2015 Accepted: August 28, 2015 Published: September 08, 2015 ABSTRACT Clinical outcomes for high-risk neuroblastoma patients remains poor, with only 40–50% 5-Year overall survival (OS) and |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|